NTRB

Nutriband Inc. NASDAQ Listed Oct 1, 2021

Healthcare ·Biotechnology ·US · nutriband.com

$3.64

Mkt Cap $44.2M

52w Low $3.42 2.7% of range 52w High $11.68

50d MA $3.96 200d MA $5.42

P/E (TTM) -1.5x

EV/EBITDA -6.2x

P/B 6.7x

Debt/Equity 0.0x

ROE -123.2%

P/FCF -10.9x

RSI (14) —

ATR (14) —

Beta 1.93

50d MA $3.96

200d MA $5.42

Avg Volume 10.9K

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

SIC Code

3842

CIK (SEC)

1676047

Phone

407 377 6695

121 South Orange Avenue · Orlando, FL 32801 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Apr 29, 2026	AMC	-1.89	-0.04	+97.9%	3.79	+0.0%	+2.1%	-0.3%	-4.1%	+10.3%	-2.7%	—
Dec 16, 2025	AMC	-2.13	-0.12	+94.4%	4.49	+2.0%	-2.0%	+3.0%	-0.9%	-2.4%	+3.4%	—
Sep 9, 2025	AMC	-0.17	-2.12	-1147.1%	6.08	+0.3%	-1.3%	+15.5%	+3.2%	-5.7%	+6.1%	—
May 30, 2025	AMC	-0.13	-0.12	+7.7%	6.50	+26.2%	+24.8%	-4.9%	+6.1%	-11.2%	+6.1%	—
Apr 28, 2025	AMC	-0.12	-0.18	-50.0%	5.84	-4.1%	-2.7%	+21.1%	-8.4%	+1.1%	+0.6%	—
Dec 3, 2024	AMC	—	-0.12	—	4.14	+7.0%	+5.1%	-6.4%	+1.2%	+0.0%	+14.3%	—
Sep 3, 2024	AMC	—	-0.12	—	4.71	-0.2%	-9.6%	-2.1%	+6.2%	-7.7%	-5.4%	—
May 31, 2024	AMC	—	-0.21	—	5.45	+1.8%	+13.0%	-3.7%	-15.0%	+6.0%	-2.6%	—
Apr 30, 2024	AMC	—	-0.16	—	3.46	-1.4%	+1.2%	+4.3%	-4.4%	-2.6%	-1.5%	—
Dec 12, 2023	AMC	—	-0.22	—	2.55	-3.1%	+4.7%	+0.0%	+0.0%	-4.9%	+0.8%	—
Sep 11, 2023	AMC	—	-0.11	—	2.85	+0.4%	-10.2%	+0.8%	+1.6%	+3.4%	-2.2%	—
Jun 9, 2023	AMC	—	-0.13	—	2.53	+0.8%	+8.3%	-1.5%	-1.9%	+4.2%	-5.8%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Jul 26	Small Cap Consumer Research	Maintains	Buy → Buy	—	$4.40	$4.48	+1.8%	+27.3%	+20.0%	-0.9%	-34.1%	-0.5%

Data updated apr 26, 2026 4:01pm · Source: massive.com